ReT01 ACT
Alternative Names: ReT01-ACTLatest Information Update: 04 Mar 2024
At a glance
- Originator Aeonvital Biomedicine
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 21 Feb 2024 The Centre for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approves IND application for ReT01 ACT in Solid tumors prior to February 2024
- 19 Feb 2024 Preclinical trials in Solid tumours in China (Parenteral)
- 14 Feb 2024 Aeonvital Biomedicine plans a phase I trial for Solid tumors (Late-stage disease) (Parenteral) in February 2024 (NCT06257680 )